Zacks Investment Research on MSN
AXS stock moves above 50 & 200-day SMA: Buy, sell or stay invested?
Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...
Zacks Investment Research on MSN
AXSM up on FDA priority review to AXS-05 sNDA in Alzheimer's agitation
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...
US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...
AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two ...
FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.
AXS, the global advanced ticketing and live event technology company, has announced two key leadership appointments as part of its continued technology transformation and global growth. Nikhil Bobde ...
Axie Infinity (AXS) has dropped by roughly 90% after peaking out at $172 in November 2021. AXS’s sharp correction has made it one of the worst-performing digital assets among the top-ranking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback